Cabaletta Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
22.1%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$1.34next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| RESET-SSc Registrational Study Initiation | 31 Dec 2026 |
| RESET-Myositis Registrational Cohort Topline Data | 30 Jun 2027 |
| Planned BLA Submission for Myositis (including JDM) | 31 Dec 2027 |
Monitoring Framework
Key Performance Indicators
Cash Runway QuarterlyTarget: Mid-2027
RESET-Myositis Registrational Cohort Enrollment QuarterlyTarget: 17 patients
RESET-SSc Registrational Study Initiation QuarterlyTarget: Initiation in 4Q26 (~25 patients)
Watch Items
- Going-concern language in SEC filingsTrigger: Removal of going-concern qualification in future 10-Q or 10-K filingsAction: Monitor quarterly financial statements and balance sheet health following the May 2026 capital raise.
- Preconditioning-free (PC-free) cohort data readoutsTrigger: Efficacy and safety data from higher-dose PC-free cohorts in lupus and PVAction: Review clinical updates anticipated in 2H26 to evaluate potential outpatient scalability.
- Cellares Cell Shuttle automated manufacturing implementationTrigger: Successful clinical manufacturing run data and GMP readiness confirmationAction: Track progress under the 10-year commercial supply agreement to ensure scalable launch readiness.
Research as of 20 Jun 2026